Designs foe phase i cancer clinical trials with differentiation of graded toxicity
From MaRDI portal
Publication:4548226
DOI10.1080/03610920008832527zbMath1012.62115OpenAlexW2016462949MaRDI QIDQ4548226
Chinying Wang, Irvin Tyan, T. Timothy Chen
Publication date: 25 September 2002
Published in: Communications in Statistics - Theory and Methods (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/03610920008832527
Related Items (7)
A system for determining maximum tolerated dose in clinical trial ⋮ Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials ⋮ Estimating the model with fixed and random effects by a robust method ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ On the consistency of the continual reassessment method with multiple toxicity constraints ⋮ The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach ⋮ The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
Cites Work
This page was built for publication: Designs foe phase i cancer clinical trials with differentiation of graded toxicity
